[go: up one dir, main page]

WO2008139947A1 - 下痢の予防又は治療剤 - Google Patents

下痢の予防又は治療剤 Download PDF

Info

Publication number
WO2008139947A1
WO2008139947A1 PCT/JP2008/058328 JP2008058328W WO2008139947A1 WO 2008139947 A1 WO2008139947 A1 WO 2008139947A1 JP 2008058328 W JP2008058328 W JP 2008058328W WO 2008139947 A1 WO2008139947 A1 WO 2008139947A1
Authority
WO
WIPO (PCT)
Prior art keywords
glu
cys
val
gly
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/058328
Other languages
English (en)
French (fr)
Inventor
Junya Yoneda
Tetsuo Yano
Yukie Seki
Yuzuru Eto
Yusuke Amino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ajinomoto Co Inc
Original Assignee
Ajinomoto Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Co Inc filed Critical Ajinomoto Co Inc
Priority to JP2009514106A priority Critical patent/JP5321452B2/ja
Priority to ES08752258.7T priority patent/ES2499015T3/es
Priority to EP08752258.7A priority patent/EP2156846B1/en
Publication of WO2008139947A1 publication Critical patent/WO2008139947A1/ja
Priority to US12/613,727 priority patent/US20100105864A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

　カルシウム受容体活性化作用を有する化合物、例えばγ－Ｇｌｕ－Ｘ－Ｇｌｙ（Ｘはアミノ酸又はアミノ酸誘導体を表す）、γ－Ｇｌｕ－Ｖａｌ－Ｙ（Ｙはアミノ酸又はアミノ酸誘導体を表す）、γ－Ｇｌｕ－Ａｌａ、γ－Ｇｌｕ－Ｇｌｙ、γ－Ｇｌｕ－Ｃｙｓ、γ－Ｇｌｕ－Ｍｅｔ、γ－Ｇｌｕ－Ｔｈｒ、γ－Ｇｌｕ－Ｖａｌ、γ－Ｇｌｕ－Ｏｒｎ、Ａｓｐ－Ｇｌｙ、Ｃｙｓ－Ｇｌｙ、Ｃｙｓ－Ｍｅｔ、Ｇｌｕ－Ｃｙｓ、Ｇｌｙ－Ｃｙｓ、Ｌｅｕ－Ａｓｐ、γ－Ｇｌｕ－Ｍｅｔ（Ｏ）、γ－Ｇｌｕ－γ－Ｇｌｕ－Ｖａｌ、γ－Ｇｌｕ－Ｖａｌ－ＮＨ2、γ－Ｇｌｕ－Ｖａｌ－ｏｌ、γ－Ｇｌｕ－Ｓｅｒ、γ－Ｇｌｕ－Ｔａｕ、γ－Ｇｌｕ－Ｃｙｓ（Ｓ－Ｍｅ）（Ｏ）、γ－Ｇｌｕ－Ｌｅｕ、γ－Ｇｌｕ－Ｉｌｅ、γ－Ｇｌｕ－ｔ－Ｌｅｕおよびγ－Ｇｌｕ－Ｃｙｓ（Ｓ－Ｍｅ）等のペプチド等を下痢の予防又は治療剤の有効成分とする。
PCT/JP2008/058328 2007-05-08 2008-05-01 下痢の予防又は治療剤 Ceased WO2008139947A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009514106A JP5321452B2 (ja) 2007-05-08 2008-05-01 下痢の予防又は治療剤
ES08752258.7T ES2499015T3 (es) 2007-05-08 2008-05-01 Agente profiláctico o terapéutico para la diarrea
EP08752258.7A EP2156846B1 (en) 2007-05-08 2008-05-01 Prophylactic or therapeutic agent for diarrhea
US12/613,727 US20100105864A1 (en) 2007-05-08 2009-11-06 Prophylactic or therapeutic agent for diarrhea

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-123765 2007-05-08
JP2007123765 2007-05-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/613,727 Continuation US20100105864A1 (en) 2007-05-08 2009-11-06 Prophylactic or therapeutic agent for diarrhea

Publications (1)

Publication Number Publication Date
WO2008139947A1 true WO2008139947A1 (ja) 2008-11-20

Family

ID=40002155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/058328 Ceased WO2008139947A1 (ja) 2007-05-08 2008-05-01 下痢の予防又は治療剤

Country Status (5)

Country Link
US (1) US20100105864A1 (ja)
EP (1) EP2156846B1 (ja)
JP (2) JP5321452B2 (ja)
ES (1) ES2499015T3 (ja)
WO (1) WO2008139947A1 (ja)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107660A1 (ja) 2008-02-25 2009-09-03 味の素株式会社 糖尿病又は肥満病の予防又は治療剤
WO2009119554A1 (ja) 2008-03-24 2009-10-01 味の素株式会社 消化管の重炭酸分泌促進剤
WO2013051685A1 (ja) 2011-10-07 2013-04-11 味の素株式会社 変異型γ－グルタミルトランスフェラーゼ、及び、γ-グルタミルバリルグリシン又はその塩の製造法
US8454978B2 (en) * 2008-04-17 2013-06-04 Ajinomoto Co., Inc. Immunostimulating agent
WO2015115612A1 (ja) 2014-01-31 2015-08-06 味の素株式会社 変異型グルタミン酸－システインリガーゼ、及び、γ－グルタミルバリルグリシンの製造法
US9253997B2 (en) 2010-03-04 2016-02-09 Ajinomoto Co., Inc. Alkylamine derivative
EP3530749A1 (en) 2018-02-27 2019-08-28 Ajinomoto Co., Inc. Glutathione synthetase mutant and method for producing gamma-glu-val-gly
US11788109B2 (en) 2015-09-04 2023-10-17 Ajinomoto Co., Inc. Microorganism and method for producing gamma-glutamyl-valyl-glycine

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4553052B2 (ja) * 2005-11-09 2010-09-29 味の素株式会社 コク味付与剤
WO2007055388A2 (en) * 2005-11-09 2007-05-18 Ajinomoto Co., Inc. Calcium receptor activator
US8420144B2 (en) * 2005-11-09 2013-04-16 Ajinomoto Co., Inc. Kokumi-imparting agent, method of using, and compositions containing same
JP5688687B2 (ja) 2009-04-01 2015-03-25 味の素株式会社 ペプチドのコク味付与用途
BR112012015700A2 (pt) 2009-12-28 2015-09-01 Ajinomoto Kk Agente realçador de umani, composição alimentícia, métodos para preparar um alimento ou uma bebida ou um intermediário e para melhorar o sabor e/ou gosto de um alimento ou uma bebida, e, alimento ou bebida, ou um intermediário
NZ600832A (en) 2009-12-28 2013-06-28 Ajinomoto Kk Lanthionine derivative and use thereof as a food composition and a kokumi-imparting agent
EP3115463B1 (en) 2014-03-05 2019-09-18 Ajinomoto Co., Inc. Method for producing gamma-glutamyl-valyl-glycine

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035983A1 (en) * 1999-11-16 2001-05-25 Karolinska Innovations Ab Pharmaceutical composition for treatment of diarrhea
WO2007027548A2 (en) * 2005-09-02 2007-03-08 Amgen Inc. Methods of modulating intestinal fluid balance
WO2007055388A2 (en) * 2005-11-09 2007-05-18 Ajinomoto Co., Inc. Calcium receptor activator
WO2007055393A1 (en) * 2005-11-09 2007-05-18 Ajinomoto Co., Inc. Kokumi-imparting agent

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1203761E (pt) * 1994-10-21 2005-04-29 Nps Pharma Inc Compostos activos do receptor de calcio
JP4117506B2 (ja) * 1996-05-01 2008-07-16 エヌピーエス ファーマシューティカルズ インコーポレイテッド 無機イオン活性化合物
PL382706A1 (pl) * 2002-08-26 2007-11-26 Takeda Pharmaceutical Company Limited Związek modulujący receptor wapnia i jego zastosowanie
US20040204577A1 (en) * 2003-01-24 2004-10-14 Ajinomoto Co., Inc. Novel peptide-forming enzyme gene
US7754677B2 (en) * 2003-12-05 2010-07-13 Hill's Pet Nutrition, Inc. Composition and method for reducing diarrhea in a mammal
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
AU2006316705B2 (en) * 2005-11-25 2011-09-29 Galapagos Sas Urea derivatives useful as calcium receptor modulators
EP2079525A1 (en) * 2006-10-26 2009-07-22 Amgen Inc. Calcium receptor modulating agents
NZ581627A (en) * 2007-05-08 2012-07-27 Ajinomoto Kk Low fat food with a calcium receptor activating additive
CN101677610B (zh) * 2007-05-08 2014-08-06 味之素株式会社 甜味剂
CA2692598A1 (en) * 2007-07-10 2009-01-15 Amgen Inc. Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
JPWO2009107660A1 (ja) * 2008-02-25 2011-07-07 味の素株式会社 糖尿病又は肥満病の予防又は治療剤
EP2275138A4 (en) * 2008-03-24 2013-08-21 Ajinomoto Kk PROMOTER FOR SECRETION OF BICARBONATE IN THE GASTROINTESTINAL TRACT
JP5685941B2 (ja) * 2008-10-03 2015-03-18 味の素株式会社 ＣａＳＲアゴニスト

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001035983A1 (en) * 1999-11-16 2001-05-25 Karolinska Innovations Ab Pharmaceutical composition for treatment of diarrhea
WO2007027548A2 (en) * 2005-09-02 2007-03-08 Amgen Inc. Methods of modulating intestinal fluid balance
WO2007055388A2 (en) * 2005-11-09 2007-05-18 Ajinomoto Co., Inc. Calcium receptor activator
WO2007055393A1 (en) * 2005-11-09 2007-05-18 Ajinomoto Co., Inc. Kokumi-imparting agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GEIBEL J. ET AL.: "Calcium-sensing receptor abrogates secretagogue-induced increases in intestinal net fluid secretion by enhancing cyclic nucleotide destruction", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 103, no. 25, 2006, pages 9390 - 9397, XP001539876 *
WANG M. ET AL.: "Activation of Family C G-protein-coupled Receptors by the Tripeptide Glutathione", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 281, no. 13, 31 March 2006 (2006-03-31), pages 8864 - 8870, XP008123658 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009107660A1 (ja) 2008-02-25 2009-09-03 味の素株式会社 糖尿病又は肥満病の予防又は治療剤
WO2009119554A1 (ja) 2008-03-24 2009-10-01 味の素株式会社 消化管の重炭酸分泌促進剤
US8454978B2 (en) * 2008-04-17 2013-06-04 Ajinomoto Co., Inc. Immunostimulating agent
US9561216B2 (en) 2010-03-04 2017-02-07 Ea Pharma Co., Ltd. Alkylamine derivative
US9253997B2 (en) 2010-03-04 2016-02-09 Ajinomoto Co., Inc. Alkylamine derivative
USRE49569E1 (en) 2010-03-04 2023-07-04 Ea Pharma Co., Ltd. Alkylamine derivative
WO2013051685A1 (ja) 2011-10-07 2013-04-11 味の素株式会社 変異型γ－グルタミルトランスフェラーゼ、及び、γ-グルタミルバリルグリシン又はその塩の製造法
US9580696B2 (en) 2011-10-07 2017-02-28 Ajinomoto Co., Inc. Method for producing γ-glutamylvalylglycine or a salt thereof
US9677106B2 (en) 2011-10-07 2017-06-13 Ajinomoto Co., Inc. Method for producing gamma-glutamylvalylglycine or a salt thereof
WO2015115612A1 (ja) 2014-01-31 2015-08-06 味の素株式会社 変異型グルタミン酸－システインリガーゼ、及び、γ－グルタミルバリルグリシンの製造法
US11788109B2 (en) 2015-09-04 2023-10-17 Ajinomoto Co., Inc. Microorganism and method for producing gamma-glutamyl-valyl-glycine
EP3530749A1 (en) 2018-02-27 2019-08-28 Ajinomoto Co., Inc. Glutathione synthetase mutant and method for producing gamma-glu-val-gly
US11142755B2 (en) 2018-02-27 2021-10-12 Ajinomoto Co., Inc. Mutant glutathione synthetase and method for producing gamma-glutamyl-valyl-glycine

Also Published As

Publication number Publication date
US20100105864A1 (en) 2010-04-29
JP5321452B2 (ja) 2013-10-23
EP2156846B1 (en) 2014-08-13
EP2156846A4 (en) 2012-03-07
JP5716791B2 (ja) 2015-05-13
JPWO2008139947A1 (ja) 2010-08-05
JP2013209402A (ja) 2013-10-10
ES2499015T3 (es) 2014-09-26
EP2156846A1 (en) 2010-02-24

Similar Documents

Publication Publication Date Title
WO2008139947A1 (ja) 下痢の予防又は治療剤
WO2008139945A1 (ja) 低脂肪食品
WO2008139946A1 (ja) 甘味料
WO2002002525A3 (en) N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity
WO2007052299A3 (en) Controlled release formulation
WO2003024401A3 (en) Piperizinones as modulators of chemokine receptor activity
WO2004012699A3 (en) Modified release composition comprising coated micro matrix particles containing the high soluble active ingredient and a release controlling agent
WO2006131737A3 (en) Method and composition for treating inflammatory disorders
WO2007127158A3 (en) Modification of percutaneous absorption of topically active materials
WO2006084164A8 (en) Gastric retention and controlled release delivery system
WO2009078447A1 (ja) 抗ノロウイルス剤、抗インフルエンザウイルス剤、およびこれらを用いた抗ウイルス処理方法
EP1864665A4 (en) IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
WO2005089718A3 (en) Pharmaceutical compositions
WO2007056073A3 (en) Medical device with a coating comprising an active form and an inactive form of therapeutic agent(s)
WO2004069138A3 (en) Pharmaceutical formulation
DK1572153T3 (da) Fremstilling af sterile vandige suspensioner, som omfatter mikroniserede krystallinske virksomme stoffer til inhalering
WO2001098270A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2001098269A3 (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
WO2005065639A3 (en) Novel pharmaceutical compositions
NO20044132L (no) Legemidler som inneholder aktive ingredienser som senker kolesterolnivaet med tidsforsinket frigjoring av det aktive middelet
EP1584335A3 (en) Active substance combination comprising a carbinol composition and an opioid
WO2006053564A3 (en) Stabilisation of granules comprising active compounds
AU2003263301A1 (en) Alternative processes for the preparation of d- (+) -morphine, and d- (+) - morphine tartrate
WO2005094265A3 (en) Self assembling activation agents targeted using active drug release
WO2007063702A3 (en) Iminopropene compound and use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08752258

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009514106

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008752258

Country of ref document: EP